Authors :
C. Aoussar; C. Nahi; M. A Ichane; K. Mouadine; B. Chkirate
Volume/Issue :
Volume 9 - 2024, Issue 10 - October
Google Scholar :
https://tinyurl.com/mrxzetzk
Scribd :
https://tinyurl.com/6zsnc3vb
DOI :
https://doi.org/10.38124/ijisrt/IJISRT24OCT257
Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.
Abstract :
Neonatal lupus erythematosus (NEL) is a rare
autoimmune disease characterized by transplacental
transmission of maternal antibodies, primarily directed
against SSA/Ro or SSB/La proteins. Clinical
manifestations include cutaneous, hematologic, hepatic,
and cardiac symptoms, including congenital
atrioventricular block (cAVB). Although cutaneous
symptoms are often reversible and treated with topical
steroids, cardiac complications, such as cAVB, are
considered irreversible and can be fatal. Pregnant women
with specific antibodies should be screened, and fetal
echocardiography is recommended for prenatal screening.
Traditional treatments include corticosteroids, although
hydroxychloroquine and intravenous immunoglobulin
(IVIG) may be effective alternatives to reduce the risk of
cardiac complications in newborns.
References :
- N. Costedoat-Chalumeau et al. “Neonatal lupus”: review of the literature. The journal of internal medicine 24 (2003) 659–671
- Lela A. Lee. Neonatal Lupus Clinical Characteristics and Management. Pediatr Drugs 2004; 6 (2)
- Morel N, et al. “Neonatal lupus”: literature review. Rev Med Interne (2014),
- J. Blanc et al. Polymorphism and differential diagnoses of neonatal lupus erythematosus. Annals of Dermatology and Venereology (2020) 147, 258—264.
- Bridge RG, Foley FE (1954) Placental transmission of the lupus erythematosus factor. Am J Med Sci 227:1–8
- Federica Vanoni. Sebastiano AG Lava. Emilio F. Fossali. Riccardo Cavalli. Giacomo D. Simonetti. Mario G. Bianchetti. Marie-Ange Bozzini. Carlo Agostoni. Gregorio P. Milani. Neonatal Systemic Lupus Erythematosus Syndrome: a Comprehensive Review. Clinic Rev Allerg Immunol. 2017.
- J. Hoebeke, S. Muller. Neonatal lupus: new hypotheses concerning immunopathogenesis. Revue du Rhumatisme 72 (2005) 159–161
- N. Costedoat-Chalumeau et al. “Neonatal lupus”: review of the literature. The journal of internal medicine 24 (2003) 659–671
- Derdulska et al. Neonatal lupus erythematosus. J. Perinat. Med. 2021; 49(5): 529–538
- Ramphul et al. Cutaneous Neonatal Lupus Erythematosus: A Case Report 2018. Cureus 10(2): e2212.
- Kam Lun Hon and Alexander KC Leung. Neonatal Lupus Erythematosus. Hindawi Publishing Corporation Autoimmune Diseases Volume 2012, 6 pages
- E. Silverman & E. Jaeggi. Neonatal Lupus Erythematosus. 2010 Scandinavian Journal of Immunology 72, 223–225.
- Benay Johnson. Overview of Neonatal Lupus. Journal of Pediatric Health Care. 2013
- R. Cimaz, A. Duquesne. Neonatal lupus. Archives of Pediatrics 13 (2006) 473–478
- Jérôme Coulombe, Julie Barsalou. Neonatal lupus manifesting as a butterfly-shaped rash. CMAJ 2021.
Neonatal lupus erythematosus (NEL) is a rare
autoimmune disease characterized by transplacental
transmission of maternal antibodies, primarily directed
against SSA/Ro or SSB/La proteins. Clinical
manifestations include cutaneous, hematologic, hepatic,
and cardiac symptoms, including congenital
atrioventricular block (cAVB). Although cutaneous
symptoms are often reversible and treated with topical
steroids, cardiac complications, such as cAVB, are
considered irreversible and can be fatal. Pregnant women
with specific antibodies should be screened, and fetal
echocardiography is recommended for prenatal screening.
Traditional treatments include corticosteroids, although
hydroxychloroquine and intravenous immunoglobulin
(IVIG) may be effective alternatives to reduce the risk of
cardiac complications in newborns.